References
- Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: Long-term follow-up review of 18 patients. Journal of Neurosurgery 1999; 91: 733–736
- Rifici C, Kofler M, Kronenberg M, Kofler A, Bramanti P, Saltuari L. Intrathecal baclofen application in patients with supraspinal spasticity secondary to severe traumatic brain injury. Functional Neurology 1994; 9: 29–34
- Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. Journal of Neurology 1997; 244: 160–166
- Cuny E, Richer E, Castel JP. Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: Relief with intrathecal baclofen therapy. Brain Injury 2001; 15: 917–925
- Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RC. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Archives of Physical and Medical Rehabilitation 2001; 82: 1155–1163
- Meythaler JM, Clayton W, Davis LK, Guin-Renfroe S, Brunner RC. Orally delivered baclofen to control spastic hypertonia in acquired brain injury. Journal of Head Trauma Rehabilitation 2004; 19: 101–108
- Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open-labeled trial. Neurology 1996; 47: 939–944